Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marisa Mariani

Showing results (1-10 of 25) with videos related to

Pageof 3
Sort By:
Current Pharmaceutical Design|March 7, 2012
Novel drugs targeting microtubules: the role of epothilonesGabriella Ferrandina, Marisa Mariani, Mirko Andreoli, et al.
Plos One|May 3, 2013
Free testosterone drives cancer aggressiveness: evidence from US population studiesShohreh Shahabi, Shiquan He, Michael Kopf, et al.
Expert Opinion on Therapeutic Targets|February 6, 2013
βIII-Tubulin: biomarker of taxane resistance or drug target?Roshan Karki, Marisa Mariani, Mirko Andreoli, et al.
Oncology Research|December 15, 2010
RON and cisplatin resistance in ovarian cancer cell linesSilvia Prislei, Marisa Mariani, Giuseppina Raspaglio, et al.
Gene|April 4, 2015
Class III β-tubulin in normal and cancer tissuesMarisa Mariani, Roshan Karki, Manuela Spennato, et al.
Plos One|September 17, 2015
Epstein-Barr Virus MicroRNA Expression Increases Aggressiveness of Solid MalignanciesDeep Pandya, Marisa Mariani, Shiquan He, et al.
BMC Cancer|February 12, 2013
MiR-200c and HuR in ovarian cancerSilvia Prislei, Enrica Martinelli, Marisa Mariani, et al.
Plos One|August 4, 2012
Adrenomedullin in ovarian cancer: foe in vitro and friend in vivo?Cinzia Baranello, Marisa Mariani, Mirko Andreoli, et al.
Plos One|July 3, 2014
Integrated multidimensional analysis is required for accurate prognostic biomarkers in colorectal cancerMarisa Mariani, Shiquan He, Mark McHugh, et al.
Biochimica Et Biophysica Acta|February 16, 2011
Investigation of the Bcl-2 multimerisation process: structural and functional implicationsAlessia Camperchioli, Marisa Mariani, Silvia Bartollino, et al.
Pageof 3

Showing results (1-10 of 25) with videos related to

Sort By:
Pageof 3
Current Pharmaceutical Design|March 7, 2012
Novel drugs targeting microtubules: the role of epothilonesGabriella Ferrandina, Marisa Mariani, Mirko Andreoli, et al.
Plos One|May 3, 2013
Free testosterone drives cancer aggressiveness: evidence from US population studiesShohreh Shahabi, Shiquan He, Michael Kopf, et al.
Expert Opinion on Therapeutic Targets|February 6, 2013
βIII-Tubulin: biomarker of taxane resistance or drug target?Roshan Karki, Marisa Mariani, Mirko Andreoli, et al.
Oncology Research|December 15, 2010
RON and cisplatin resistance in ovarian cancer cell linesSilvia Prislei, Marisa Mariani, Giuseppina Raspaglio, et al.
Gene|April 4, 2015
Class III β-tubulin in normal and cancer tissuesMarisa Mariani, Roshan Karki, Manuela Spennato, et al.
Plos One|September 17, 2015
Epstein-Barr Virus MicroRNA Expression Increases Aggressiveness of Solid MalignanciesDeep Pandya, Marisa Mariani, Shiquan He, et al.
BMC Cancer|February 12, 2013
MiR-200c and HuR in ovarian cancerSilvia Prislei, Enrica Martinelli, Marisa Mariani, et al.
Plos One|August 4, 2012
Adrenomedullin in ovarian cancer: foe in vitro and friend in vivo?Cinzia Baranello, Marisa Mariani, Mirko Andreoli, et al.
Plos One|July 3, 2014
Integrated multidimensional analysis is required for accurate prognostic biomarkers in colorectal cancerMarisa Mariani, Shiquan He, Mark McHugh, et al.
Biochimica Et Biophysica Acta|February 16, 2011
Investigation of the Bcl-2 multimerisation process: structural and functional implicationsAlessia Camperchioli, Marisa Mariani, Silvia Bartollino, et al.
Pageof 3